Glenmark Pharmaceuticals has launched a triple-fixed-dose combination drug called Zita for the treatment of Type 2 diabetes. The drug, which combines Teneligliptin, Dapagliflozin, and Metformin, is priced at Rs 14 per tablet and aims to improve glycemic control in diabetic patients. The medication is expected to lower the daily cost of therapy by 30%, making it more affordable for patients.
Related Keywords
Mumbai ,Maharashtra ,India ,Alok Malik ,Glenmark Pharma ,Glenmark Pharmaceuticals On ,Glenmark Pharmaceuticals ,Pharma President ,Business Head ,India Formulations ,Glenmark ,Dzita ,Dapagliflozin ,Fdc ,
comparemela.com © 2020. All Rights Reserved.